Leprosy pathogenetic background: a review and lessons from other mycobacterial diseases.
Leprosy is a disease caused by Mycobacterium leprae that initially affects the peripheral nervous system with patients exhibiting contrasting clinical, immunological, and pathological manifestations despite minimal genetic variation among bacilli isolates. Its clinical manifestations are related to M. leprae survival, innate and acquired immune responses, and interactions between host and bacterial proteins, preventing their invasion and infection, or promoting their development and pathogenesis. The complex molecular interactions in affected individuals influenced by the pathogenetic background will be explored in this review. However, the great genetic diversity imposes difficulty for understanding disease development, and it is likely that many factors and metabolic pathways regulating the immense and contrasting symptomatology will yet be revealed. Four pathways may play a central role in leprosy, including the TLR/LIR-7, VDR, TNF-alpha, and TGF-beta1 for which a large amount of gene polymorphisms have been described that could potentially affect the clinical outcome. Cross-talk pathways may significantly change the course of the disease, depending on the specific disequilibrium of genic homeostasis, which is highly dependent on the environment, antigens that are presented to the host cell, and specific polymorphisms that interact with other genes, external factors, and pathogen survival, culminating in leprosy occurrence. Currently, the microarray-based genomic survey of gene polymorphisms, multiple gene expression analyses, and proteomic technologies, such as mass spectrometry and phage display applied in the discovery of antigens, represent a great potential for evaluating individual responses of leprosy patients and contacts to predict the outcome and progression of the disease. At present, none of the genes is good prognostic marker; however, in the near future we may use multiple targets to predict infection and leprosy development.
Goulart
Luiz Ricardo
LR
National Reference Center of Sanitary Dermatology and Leprosy, Clínic's Hospital, School of Medicine, Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil. lrgoulart@ufu.br
Goulart
Isabela Maria Bernardes
IM
D006801:Humans; D007918:Leprosy / Q000235:genetics* / Q000473:pathology; D009164:Mycobacterium Infections / Q000235:genetics* / Q000473:pathology; D009166:Mycobacterium leprae / Q000472:pathogenicity*; D011110:Polymorphism, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics; D051193:Toll-Like Receptors / Q000235:genetics; D053773:Transforming Growth Factor beta1 / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D018167:Receptors, Calcitriol; D051193:Toll-Like Receptors; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha